1. Clinical features and prognosis of cardiac metastatic tumors
- Author
-
Zhongqiao Lin, Huazhen Xiao, Jun Liu, Ling Chen, Huishan Zhang, Yufang Huang, Yu Chen, and Jing Lin
- Subjects
Tumor ,Cardiac metastasis ,Cancer survivorship ,Cardiac function ,Echocardiography ,Efficacy evaluation ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background This study aimed to explore the clinical features and prognosis of cardiac metastatic tumors. In addition, whether continuing antitumor therapy after the development of cardiac metastases can benefit patients and the response of cardiac metastases were investigated. Methods A retrospective analysis was conducted on patients with malignancies who were admitted to Fujian Cancer Hospital and Fujian Provincial Hospital from January 2007 to September 2022, and the follow-up period ended in March 2023. Clinical data were gathered, treatment efficacy was evaluated, and survival analysis was performed. Results After the patients developed cardiac metastasis, the overall 30-day, 3-month, 6-month, and 12-month survival rates were 85.00%, 59.00%, 51.00% and 38.00%, respectively. With continued treatment, the average survival time was 27.33 months (95% confidence interval [CI]: 16.88–37.79), which exceeded the 6.6 months (95% confidence interval [CI]: 0.03–13.69) observed for patients who withdrew from treatment (P
- Published
- 2023
- Full Text
- View/download PDF